This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look: Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.
Ticker(s): JNJ, ABBV, BMY, AMGN, LLYWho's the expert?
- Treats Approximately 90 patients per month with plaque psoriasis
- Has read the publicly available information and can discuss Tyk2 clinically and how they will be a part of the treatment modalities.
- Dermatologist and clinical faculty at the University of Pennsylvania
Interview GoalTo discuss the standard of care and the potential of JNJ-2113, an oral interleukin-23 receptor (IL-23R) antagonist peptide being developed by Johnson & Johnson.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
